Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims Data on glucose and cardiovascular disease (CVD) risk factor control among persons with type 2 diabetes mellitus (DM) according to insulin treatment status are lacking. We examined DM control, risk factors, and comorbidities among U.S. persons according to insulin treatment status. Methods In the U.S. National Health and Nutrition Examination Surveys 2003–2006, we examined in 10,637 adults aged ≥30 with type 2 DM the extent of control of A1c, LDL-C, HDL-C, triglycerides, and blood pressure (BP) and composite goal attainment by insulin use status. Results 6.6% (n=889, projected to 14.3 million) had type 2 DM; of these, 22.9% were insulin users and 57.2% were treated only by other diabetes medications. Overall, 58.2% had an A1c<7% (53 mmol/mol) (insulin users 33.1%, non-insulin treated 66.1%, and 77.9% of those not on medication, p<0.0001). Overall, 44.2% were at a BP goal of <130/80 mmHg, 43.8% had an LDL-C<100 mg/dl (2.6 mmol/L), and 13.9% a BMI<25 kg/m2. Only 10.2% were simultaneously at A1c, LDL, and BP goals (5.4% of those on insulin). Conclusions U.S. adults with type 2 DM, especially those treated with insulin remain inadequately controlled for A1c and CVD risk factors and have a high prevalence of comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“While some key trials (Knowler et al., 2002; Tuomilehto et al., 2001) have documented the value of lifestyle changes to prevent DM in those with pre-diabetes, the counseling and monitoring that were available in these trials are not typical of what is normally available in clinical practice, thus resources need to be…”
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 2×
“…to reduce the risk of CVD events in persons with diabetes, and control of blood sugar results in substantial reductions in microvascular complications (Buse et al., 2007; Colhoun et al., 2004; Collins et al., 2003; Keech et al., 2003; Vijan and Hayward, 2004; Zeber & Parchman, 2010).”
Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006
Cowie, C. C., Rust, K. F., Ford, E. S., Eberhardt, M. S., Byrd-Holt, D. D., Li, C., Williams, D. E., Gregg, E. W., Bainbridge, K. E., Saydah, S. H., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1296 · Cited by 1,154
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055 · cited 2×
“…to reduce the risk of CVD events in persons with diabetes, and control of blood sugar results in substantial reductions in microvascular complications (Buse et al., 2007; Colhoun et al., 2004; Collins et al., 2003; Keech et al., 2003; Vijan and Hayward, 2004; Zeber & Parchman, 2010).”
InfluentialKeech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313 · cited 4×
“Well-established from clinical trials is the efficacy of both antihypertensive and statin therapy in reducing CVD event risk in diabetes.(Chobanian et al., 2003; Colhoun et al., 2004; Collins et al., 2003; Keech et al., 2003; Hansson et al., 1998; Vijan and Hayward, 2004).”
InfluentialGhandehari, H., Kamal-Bahl, S., & Wong, N. D. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.005 · Cited by 180
Self-citationUS Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes
Shaya, F. T., Yan, X., Lin, P., Simoni‐Wastila, L., Bron, M., Baran, R., & Donner, T. W. (2010) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00365.x · Cited by 29 · cited 3×
“Earlier reports also document similarly poor achievement of glycemic, BP, and lipid goals (Imperatore et al., 2004; Saydah et al., 2003), as well as a high burden of comorbidities, particularly in older persons (Shaya et al., 2010).”
Research works printed but not linked: 21
- Ahmann, 2007, Guidelines and performance measures for diabetes, The American Journal of Managed Care, 13, S41
- American Diabetes Association, 2011, Executive summary: standards for medical care in diabetes—2011, Diabetes Care, 34, s4
- Bertoni, 2008, Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study, Journal of Diabetes and its Complications, 22, 1, 10.1016/j.jdiacomp.2006.10.003 · DOI
- Bouchi, 2010, Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes, Hypertension Research: Official Journal of the Japanese Society of Hypertension, 10.1038/hr.2010.170 · DOI
- Breen, 2011, Effects of insulin on the vasculature, Current Vascular Pharmacology, 9, 321, 10.2174/157016111795495558 · doi:10.2174/157016111795495558
- Cheung, 2009, Diabetes prevalence and therapeutic target achievement in the United States, 1999–2006, The American Journal of Medicine, 122, 443, 10.1016/j.amjmed.2008.09.047 · DOI · Paper page
- Chobanian, 2003, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA: The Journal of The American Medical Association, 289, 2560, 10.1001/jama.289.19.2560 · DOI · Paper page
- Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 · DOI · Paper page
- Imperatore, 2004, Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971–2000, American Journal of Epidemiology, 160, 531, 10.1093/aje/kwh232 · DOI · Paper page
- Kemp, 2005, Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes, Diabetes Care, 28, 1490, 10.2337/diacare.28.6.1490 · DOI · Paper page
- Koopman, 2005, Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000, Annals of Family Medicine, 3, 60, 10.1370/afm.214 · DOI · Paper page
- Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation, Annals of Internal Medicine, 130, 461, 10.7326/0003-4819-130-6-199903160-00002 · DOI · Paper page
- Malik, 2007, Untreatment of cardiovascular risk factors among persons with diabetes in the United States, Diabetes Research and Clinical Practice, 77, 126, 10.1016/j.diabres.2006.10.016 · DOI
- National Kidney Foundation, 2002, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation, s198
- Nichols, 2000, Achieving further glycemic control in type 2 diabetes mellitus, The Western Journal of Medicine, 173, 175, 10.1136/ewjm.173.3.175 · doi:10.1136/ewjm.173.3.175
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 13, 1, 10.4158/EP.13.S1.1 · DOI · Paper page
- Saydah, 2003, Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes, JAMA: the Journal of the American Medical Association, 26, 2713
- 2008, Effects of intensive glucose lowering in type 2 diabetes, The New England Journal of Medicine, 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
- Vijan, 2004, Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians, Annals of Internal Medicine, 140, 650, 10.7326/0003-4819-140-8-200404200-00013 · DOI · Paper page
- Wong, 2007, High prevalence and treatment rates, but inadequate control of hypertension in U.S. persons in 2003–2004 with cardiovascular disease comorbidities, Archives of Internal Medicine, 167, 2437, 10.1001/archinte.167.22.2431 · DOI · Paper page
- Zeber, 2010, Cardiovascular disease in type 2 diabetes: attributable risk due to modifiable risk factors, Canadian Family Physician Medecin de Famille Canadien, 56, e302
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
Ikramuddin, S., Korner, J., Lee, W.-J., Connett, J. E., Inabnet, W. B., Billington, C. J., Thomas, A. J., Leslie, D. B., Chong, K., Jeffery, R. W., et al. (2013) · JAMA · doi:10.1001/jama.2013.5835 · Cited by 735
Cummings, D. E., Arterburn, D. E., Westbrook, E. O., Kuzma, J. N., Stewart, S. D., Chan, C. P., Bock, S. N., Landers, J. T., Kratz, M., Foster-Schubert, K. E., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3903-x · Cited by 314
Ikramuddin, S., Korner, J., Lee, W.-J., Thomas, A. J., Connett, J. E., Bantle, J. P., Leslie, D. B., Wang, Q., Inabnet, W. B., Jeffery, R. W., et al. (2018) · JAMA · doi:10.1001/jama.2017.20813 · Cited by 291
“Triple End Point 1 16 (8 to 31) 50 (34 to 66) 34 (14-54) 5.”
InfluentialRibaric, G., Buchwald, J. N., & McGlennon, T. W. (2014) · Obesity Surgery · doi:10.1007/s11695-013-1160-3 · Cited by 264
Metadata
- Authors
- Wong, K., Glovaci, D., Malik, S., Franklin, S. S., Wygant, G., Iloeje, U., Kan, H., & Wong, N. D.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 26
- Issue
- 3
- Pages
- 169-174
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W2100758175
- Cited by
- 62
- References
- 10
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Bristol Myers-Squibb
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.